P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial
Patrícia O. Guimarães, Marcelo Franken, Caio A.M. Tavares, Fábio Serra Silveira, Murillo de Oliveira Antunes, Ricardo Reinaldo Bergo, Rodrigo M Joaquim, Jessica C S Hirai, Pedro Beraldo de Andrade, Fábio Grunspun Pitta, José Mariani, Bruno Ramos Nascimento, João Eduardo Tinoco de Paula, Marcos S. Silveira, Tiberio A O Costa, Frederico Toledo Campo Dall’Orto, Renato G Serpa, Fernanda B A Sampaio, Louis N Ohe, Fernanda Mangione, Remo H.M. Furtado, Rogério Sarmento‐Leite, Frederico Monfardini, Silvia Regina Lamas Assis, José Carlos Nicolau, Andrei C. Spósito, Renato D. Lópes, Yoshinobu Onuma, Marco Valgimigli, Dominick J. Angiolillo, Patrick W. Serruys, Otávio Berwanger, Fernando Bacal, Pedro A. Lemos (2023). P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial. EuroIntervention, 19(4), pp. e323-e329, DOI: 10.4244/eij-d-23-00125.
